Free Cash Flow (Quarterly) Chart

View Free Cash Flow (Quarterly) for RLAY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Free Cash Flow (Quarterly) Chart
Start Trial

Historical Free Cash Flow (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 -54.11M
March 31, 2026 -51.11M
December 31, 2025 -44.87M
September 30, 2025 -62.12M
June 30, 2025 -55.29M
March 31, 2025 -73.59M
December 31, 2024 -57.87M
September 30, 2024 -75.31M
June 30, 2024 -65.84M
March 31, 2024 -52.10M
December 31, 2023 -89.31M
September 30, 2023 -75.99M
June 30, 2023 -70.10M
March 31, 2023 -69.04M
December 31, 2022 -59.40M
Date Value
September 30, 2022 -68.24M
June 30, 2022 -58.95M
March 31, 2022 -51.97M
December 31, 2021 -40.59M
September 30, 2021 -54.94M
June 30, 2021 -28.52M
March 31, 2021 46.16M
December 31, 2020 -35.34M
September 30, 2020 -24.47M
June 30, 2020 -21.26M
March 31, 2020 -23.35M
December 31, 2019 -23.36M
September 30, 2019 -19.89M
June 30, 2019 -16.93M
March 31, 2019 -13.96M

Free Cash Flow Definition

Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.

Read full definition.

Free Cash Flow (Quarterly) Range, Past 5 Years

View Free Cash Flow (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Free Cash Flow (Quarterly) Benchmarks

View Free Cash Flow (Quarterly) Benchmarks
Start Trial
AbbVie, Inc. 3.114B
TG Therapeutics, Inc. 38.97M
Karyopharm Therapeutics, Inc. -24.93M
Krystal Biotech, Inc. 71.22M
Akebia Therapeutics, Inc. 2.446M